Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202). (March 2023)
- Record Type:
- Journal Article
- Title:
- Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202). (March 2023)
- Main Title:
- Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202)
- Authors:
- Ashina, Sait
Melo-Carrillo, Agustin
Szabo, Edina
Borsook, David
Burstein, Rami - Abstract:
- Background: Migraine is a complex neurological disorder involving generalized abnormalities in processing sensory information. Adopting evidence that central sensitization imposes major hurdles in the treatment of migraine, we hypothesized that it is the non-ictal (rather than ictal) allodynia that may determine the outcome of migraine prevention with peripherally-acting drugs. Methods: To test this hypothesis, we used Quantitative Sensory Testing to determine whether it is possible to identify a patient's response to prophylactic treatment with galcanezumab based on presence/absence of cephalic and/or extracephalic allodynia during the pre-treatment non-ictal phase of migraine. Results: Using strict criteria for allodynia (heat 32–40°C, cold 32–20°C, mechanical <60 g), we report that (a) the incidence of pre-treatment non-ictal cephalic allodynia was 21% in the 24 responders (>50% decrease in monthly migraine days) and 85% in the 19 non-responders; (b) the incidence of non-ictal extracephalic allodynia distinguishes responders from non-responders less accurately; and that (c) the incidence of non-ictal cephalic allodynia was similar in the chronic migraine and high-frequency episodic migraine groups. Conclusions: Clinically, the findings suggest that presence/absence of non-ictal allodynia can be used to identify galcanezumab responders with nearly 80% accuracy and galcanezumab non-responders with nearly 85% accuracy. Mechanistically, the presence of non-ictal allodyniaBackground: Migraine is a complex neurological disorder involving generalized abnormalities in processing sensory information. Adopting evidence that central sensitization imposes major hurdles in the treatment of migraine, we hypothesized that it is the non-ictal (rather than ictal) allodynia that may determine the outcome of migraine prevention with peripherally-acting drugs. Methods: To test this hypothesis, we used Quantitative Sensory Testing to determine whether it is possible to identify a patient's response to prophylactic treatment with galcanezumab based on presence/absence of cephalic and/or extracephalic allodynia during the pre-treatment non-ictal phase of migraine. Results: Using strict criteria for allodynia (heat 32–40°C, cold 32–20°C, mechanical <60 g), we report that (a) the incidence of pre-treatment non-ictal cephalic allodynia was 21% in the 24 responders (>50% decrease in monthly migraine days) and 85% in the 19 non-responders; (b) the incidence of non-ictal extracephalic allodynia distinguishes responders from non-responders less accurately; and that (c) the incidence of non-ictal cephalic allodynia was similar in the chronic migraine and high-frequency episodic migraine groups. Conclusions: Clinically, the findings suggest that presence/absence of non-ictal allodynia can be used to identify galcanezumab responders with nearly 80% accuracy and galcanezumab non-responders with nearly 85% accuracy. Mechanistically, the presence of non-ictal allodynia (reflecting a state of activity-independent central sensitization) in both chronic migraine and high-frequency episodic migraine patients raises the possibility that the state of non-ictal allodynia may be attributed to physiological properties of central trigeminovascular neurons that are due to the genetic load of the individual patient rather than their migraine frequency. … (more)
- Is Part Of:
- Cephalalgia. Volume 43:Number 3(2023)
- Journal:
- Cephalalgia
- Issue:
- Volume 43:Number 3(2023)
- Issue Display:
- Volume 43, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 43
- Issue:
- 3
- Issue Sort Value:
- 2023-0043-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2023-03
- Subjects:
- Allodynia -- galcanezumab -- headache -- trigeminal -- CGRP monoclonal antibodies
Headache -- Periodicals
616.8491 - Journal URLs:
- http://cep.sagepub.com/ ↗
http://firstsearch.oclc.org/journal=0333-1024;screen=info;ECOIP ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=cha ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/03331024221147881 ↗
- Languages:
- English
- ISSNs:
- 0333-1024
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3113.691000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26476.xml